<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Aldeyra Therapeutics, Inc</title> <link>https://www.globenewswire.com/rssfeed/organization/VvY2qUTX7IvYw_tYSicEJQ==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2017, Aldeyra Therapeutics, Inc</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Wed, 17 May 2017 12:00:00 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/05/17/1082098/0/en/Aldeyra-Therapeutics-Presents-Noninfectious-Anterior-Uveitis-Phase-2-Clinical-Trial-Data-at-the-Association-for-Research-in-Vision-and-Ophthalmology-2017-Annual-Meeting.html</guid> <link>https://www.globenewswire.com/news-release/2017/05/17/1082098/0/en/Aldeyra-Therapeutics-Presents-Noninfectious-Anterior-Uveitis-Phase-2-Clinical-Trial-Data-at-the-Association-for-Research-in-Vision-and-Ophthalmology-2017-Annual-Meeting.html</link> <title>Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting </title> <description><![CDATA[<p><em><p>Data Demonstrate ADX-102 Activity Comparable to Topical Ocular Corticosteroids But Without Known Corticosteroid Side Effects</p></em></p><p>LEXINGTON, MA--(Marketwired - May 17, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, presented the results of a randomized, multi-center, investigator-masked, comparator-controlled, parallel-group Phase 2 clinical trial of topical ocular ADX-102, a first-in-class aldehyde trap, as an Emerging Treatments paper at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting. Data from the trial demonstrated ADX-102 activity comparable to standard-of-care topical ocular corticosteroids in reducing anterior chamber cell count in patients with active noninfectious anterior uveitis (NAU). Unlike corticosteroid therapy, ADX-102 did not increase intraocular pressure, a major corticosteroid side effect that can lead to glaucoma, a potentially blinding chronic condition. Dr. John Sheppard, an internationally recognized expert in ocular inflammation, gave the presentation which is available on the investor relations page of the Aldeyra Therapeutics corporate website at <a rel="nofollow" href="http://www.aldeyra.com/" title="ir.aldeyra.com">ir.aldeyra.com</a>. </p>]]></description> <pubDate>Wed, 17 May 2017 12:00 GMT</pubDate> <dc:identifier>1082098</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/05/15/1082096/0/en/Aldeyra-Therapeutics-Provides-Corporate-Update-and-Announces-First-Quarter-2017-Financial-Results.html</guid> <link>https://www.globenewswire.com/news-release/2017/05/15/1082096/0/en/Aldeyra-Therapeutics-Provides-Corporate-Update-and-Announces-First-Quarter-2017-Financial-Results.html</link> <title>Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results </title> <description><![CDATA[<p><em><p>Significant Platform Advancement Across Four Clinical Programs</p> <p>Details Provided on 2017 and 2018 Catalysts</p></em></p><p>LEXINGTON, MA--(Marketwired - May 15, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today provided a corporate update and announced its financial results for the quarter ended March 31, 2017.</p>]]></description> <pubDate>Mon, 15 May 2017 11:30 GMT</pubDate> <dc:identifier>1082096</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/05/08/1082094/0/en/Aldeyra-Therapeutics-Schedules-Webcast-and-Conference-Call-to-Provide-Corporate-Update-and-First-Quarter-2017-Financial-Results.html</guid> <link>https://www.globenewswire.com/news-release/2017/05/08/1082094/0/en/Aldeyra-Therapeutics-Schedules-Webcast-and-Conference-Call-to-Provide-Corporate-Update-and-First-Quarter-2017-Financial-Results.html</link> <title>Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - May 8, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced it will provide a corporate update and issue financial results for the quarter ended March 31, 2017, on Monday, May 15, 2017, prior to the market open.</p>]]></description> <pubDate>Mon, 08 May 2017 12:00 GMT</pubDate> <dc:identifier>1082094</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/27/1082092/0/en/Aldeyra-Therapeutics-Announces-First-Patient-Enrolled-in-Noninfectious-Anterior-Uveitis-Phase-3-Clinical-Trial.html</guid> <link>https://www.globenewswire.com/news-release/2017/04/27/1082092/0/en/Aldeyra-Therapeutics-Announces-First-Patient-Enrolled-in-Noninfectious-Anterior-Uveitis-Phase-3-Clinical-Trial.html</link> <title>Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Apr 27, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes, today announced that it has enrolled the first patient in a Phase 3 clinical trial of topical ocular ADX-102 for the treatment of noninfectious anterior uveitis (NAU)<strong>.</strong></p>]]></description> <pubDate>Thu, 27 Apr 2017 12:00 GMT</pubDate> <dc:identifier>1082092</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/20/1082090/0/en/Aldeyra-Therapeutics-Inc-Receives-Orphan-Drug-Designation-from-the-U-S-Food-and-Drug-Administration-for-ADX-102-in-Sj%C3%B6gren-Larsson-Syndrome.html</guid> <link>https://www.globenewswire.com/news-release/2017/04/20/1082090/0/en/Aldeyra-Therapeutics-Inc-Receives-Orphan-Drug-Designation-from-the-U-S-Food-and-Drug-Administration-for-ADX-102-in-Sj%C3%B6gren-Larsson-Syndrome.html</link> <title>Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Apr 20, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a clinical-stage biotech company devoted to treating diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules, today announced that the United States Food and Drug Administration (FDA) has granted Aldeyra's novel compound ADX-102 orphan drug designation for the treatment of congenital ichthyosis, a severe skin disease characteristic of Sjögren-Larsson Syndrome (SLS). There are no FDA-approved therapies specifically indicated for the treatment of SLS, and ADX-102 is believed to be the only potential SLS therapy in clinical development. </p>]]></description> <pubDate>Thu, 20 Apr 2017 12:00 GMT</pubDate> <dc:identifier>1082090</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/18/1082089/0/en/Aldeyra-Therapeutics-Inc-Announces-Last-Patient-Dosed-in-Allergic-Conjunctivitis-Phase-2b-Clinical-Trial.html</guid> <link>https://www.globenewswire.com/news-release/2017/04/18/1082089/0/en/Aldeyra-Therapeutics-Inc-Announces-Last-Patient-Dosed-in-Allergic-Conjunctivitis-Phase-2b-Clinical-Trial.html</link> <title>Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Apr 18, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes, today announced that the last patient has completed dosing in Aldeyra's multi-center, double-blind, randomized Phase 2b clinical trial of ADX-102 in allergic conjunctivitis. </p>]]></description> <pubDate>Tue, 18 Apr 2017 12:00 GMT</pubDate> <dc:identifier>1082089</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/30/1082087/0/en/Aldeyra-Therapeutics-Reports-Full-Year-2016-Financial-Results.html</guid> <link>https://www.globenewswire.com/news-release/2017/03/30/1082087/0/en/Aldeyra-Therapeutics-Reports-Full-Year-2016-Financial-Results.html</link> <title>Aldeyra Therapeutics Reports Full Year 2016 Financial Results </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Mar 30, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes, today announced its financial results for the year ended December 31, 2016.</p>]]></description> <pubDate>Thu, 30 Mar 2017 12:00 GMT</pubDate> <dc:identifier>1082087</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/22/1082084/0/en/Aldeyra-Therapeutics-Schedules-Webcast-and-Conference-Call-for-Full-Year-2016-Financial-Results.html</guid> <link>https://www.globenewswire.com/news-release/2017/03/22/1082084/0/en/Aldeyra-Therapeutics-Schedules-Webcast-and-Conference-Call-for-Full-Year-2016-Financial-Results.html</link> <title>Aldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Mar 22, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced it will issue financial results for the year ended December 31, 2016 on Thursday, March 30, 2017, prior to the market open.</p>]]></description> <pubDate>Wed, 22 Mar 2017 12:00 GMT</pubDate> <dc:identifier>1082084</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/28/1082080/0/en/Aldeyra-Therapeutics-to-Present-at-the-Cowen-and-Company-37th-Annual-Health-Care-Conference.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/28/1082080/0/en/Aldeyra-Therapeutics-to-Present-at-the-Cowen-and-Company-37th-Annual-Health-Care-Conference.html</link> <title>Aldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Feb 28, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017.</p>]]></description> <pubDate>Tue, 28 Feb 2017 13:00 GMT</pubDate> <dc:identifier>1082080</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/22/1082075/0/en/Aldeyra-Therapeutics-Launches-the-Aldeyra-Registry-for-Patients-with-Sj%C3%B6gren-Larsson-Syndrome.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/22/1082075/0/en/Aldeyra-Therapeutics-Launches-the-Aldeyra-Registry-for-Patients-with-Sj%C3%B6gren-Larsson-Syndrome.html</link> <title>Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Feb 22, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has developed and launched the Aldeyra Registry for Sjögren-Larsson Syndrome (SLS), a rare inborn error of aldehyde metabolism that is characterized by severe skin and neurological disease. The Aldeyra Registry for SLS is designed to unite SLS patients worldwide, and to raise awareness of the significant physical challenges associated with the disease. </p>]]></description> <pubDate>Wed, 22 Feb 2017 13:00 GMT</pubDate> <dc:identifier>1082075</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/17/1082072/0/en/Aldeyra-Therapeutics-Inc-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/17/1082072/0/en/Aldeyra-Therapeutics-Inc-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html</link> <title>Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Feb 17, 2017) -  Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the closing of its previously announced underwritten public offering. Aldeyra sold 2,555,555 shares of its common stock, including 333,333 shares sold in connection with the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds of the offering, including the full exercise of the option, were approximately $10.5 million, after deducting the underwriting discounts and commissions and the other estimated offering expenses payable by Aldeyra.</p>]]></description> <pubDate>Fri, 17 Feb 2017 21:01 GMT</pubDate> <dc:identifier>1082072</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/13/1082068/0/en/Aldeyra-Therapeutics-Inc-Proposes-Public-Offering-of-Common-Stock.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/13/1082068/0/en/Aldeyra-Therapeutics-Inc-Proposes-Public-Offering-of-Common-Stock.html</link> <title>Aldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Feb 13, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aldeyra also expects to grant the underwriters a 30-day option to purchase additional shares of common stock. All of the shares in the offering are to be sold by Aldeyra, with net proceeds to be used for the continued development of Aldeyra's lead compound, ADX-102, and other product candidates, including further clinical testing of ADX-102, as well as for research and development activities, working capital and other general corporate purposes. </p>]]></description> <pubDate>Mon, 13 Feb 2017 21:01 GMT</pubDate> <dc:identifier>1082068</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/07/1082064/0/en/Aldeyra-Therapeutics-Announces-First-Patient-Enrolled-in-Allergic-Conjunctivitis-Phase-2b-Clinical-Trial.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/07/1082064/0/en/Aldeyra-Therapeutics-Announces-First-Patient-Enrolled-in-Allergic-Conjunctivitis-Phase-2b-Clinical-Trial.html</link> <title>Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Feb 7, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has enrolled the first patient in a Phase 2b clinical trial of ADX-102 for the treatment of allergic conjunctivitis.</p>]]></description> <pubDate>Tue, 07 Feb 2017 13:00 GMT</pubDate> <dc:identifier>1082064</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/06/1082061/0/en/Aldeyra-Therapeutics-to-Participate-at-the-2017-Rare-Disease-Biopharma-One-on-One-Day.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/06/1082061/0/en/Aldeyra-Therapeutics-to-Participate-at-the-2017-Rare-Disease-Biopharma-One-on-One-Day.html</link> <title>Aldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Feb 6, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate at the 2017 Rare Disease, Biopharma One-on-One Day on Tuesday, February 7, 2017.</p>]]></description> <pubDate>Mon, 06 Feb 2017 13:00 GMT</pubDate> <dc:identifier>1082061</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/01/25/1082057/0/en/Aldeyra-Therapeutics-Announces-Clinical-Development-Update-for-Phase-3-Programs.html</guid> <link>https://www.globenewswire.com/news-release/2017/01/25/1082057/0/en/Aldeyra-Therapeutics-Announces-Clinical-Development-Update-for-Phase-3-Programs.html</link> <title>Aldeyra Therapeutics Announces Clinical Development Update for Phase 3 Programs </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Jan 25, 2017) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>)</p>]]></description> <pubDate>Wed, 25 Jan 2017 13:00 GMT</pubDate> <dc:identifier>1082057</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/22/1082052/0/en/Aldeyra-Therapeutics-to-Present-at-the-28th-Annual-Piper-Jaffray-Healthcare-Conference.html</guid> <link>https://www.globenewswire.com/news-release/2016/11/22/1082052/0/en/Aldeyra-Therapeutics-to-Present-at-the-28th-Annual-Piper-Jaffray-Healthcare-Conference.html</link> <title>Aldeyra Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Nov 22, 2016) - Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 28<sup>th</sup> Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 at the Lotte New York Palace Hotel, New York.</p>]]></description> <pubDate>Tue, 22 Nov 2016 13:00 GMT</pubDate> <dc:identifier>1082052</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/14/1082049/0/en/Aldeyra-Therapeutics-Announces-Third-Quarter-2016-Financial-Results.html</guid> <link>https://www.globenewswire.com/news-release/2016/11/14/1082049/0/en/Aldeyra-Therapeutics-Announces-Third-Quarter-2016-Financial-Results.html</link> <title>Aldeyra Therapeutics Announces Third Quarter 2016 Financial Results </title> <description><![CDATA[<p><em><p>On Track to Initiate Two Phase II and Two Phase III Trials in 2017</p></em></p><p>LEXINGTON, MA--(Marketwired - Nov 14, 2016) -  Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported third quarter 2016 financial results.</p>]]></description> <pubDate>Mon, 14 Nov 2016 12:30 GMT</pubDate> <dc:identifier>1082049</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra </dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/09/1082045/0/en/Aldeyra-Therapeutics-to-Present-at-the-Stifel-2016-Healthcare-Conference.html</guid> <link>https://www.globenewswire.com/news-release/2016/11/09/1082045/0/en/Aldeyra-Therapeutics-to-Present-at-the-Stifel-2016-Healthcare-Conference.html</link> <title>Aldeyra Therapeutics to Present at the Stifel 2016 Healthcare Conference </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Nov 9, 2016) -  Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016 at the Lotte New York Palace Hotel, New York.</p>]]></description> <pubDate>Wed, 09 Nov 2016 13:00 GMT</pubDate> <dc:identifier>1082045</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/08/1082041/0/en/Aldeyra-Therapeutics-Schedules-Webcast-and-Conference-Call-for-Third-Quarter-2016-Financial-Results.html</guid> <link>https://www.globenewswire.com/news-release/2016/11/08/1082041/0/en/Aldeyra-Therapeutics-Schedules-Webcast-and-Conference-Call-for-Third-Quarter-2016-Financial-Results.html</link> <title>Aldeyra Therapeutics Schedules Webcast and Conference Call for Third Quarter 2016 Financial Results </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Nov 8, 2016) -  Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced it will issue financial results for the third quarter ended September 30, 2016 on Monday, November 14, 2016, prior to the market open.</p>]]></description> <pubDate>Tue, 08 Nov 2016 13:00 GMT</pubDate> <dc:identifier>1082041</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/07/1082036/0/en/Aldeyra-Therapeutics-Announces-Presentation-of-Phase-2-Allergic-Conjunctivitis-Results-at-the-2016-American-College-of-Allergy-Asthma-and-Immunology-Annual-Scientific-Meeting.html</guid> <link>https://www.globenewswire.com/news-release/2016/11/07/1082036/0/en/Aldeyra-Therapeutics-Announces-Presentation-of-Phase-2-Allergic-Conjunctivitis-Results-at-the-2016-American-College-of-Allergy-Asthma-and-Immunology-Annual-Scientific-Meeting.html</link> <title>Aldeyra Therapeutics Announces Presentation of Phase 2 Allergic Conjunctivitis Results at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting </title> <description><![CDATA[<p>LEXINGTON, MA--(Marketwired - Nov 7, 2016) -  Aldeyra Therapeutics, Inc. (<exchange name="NASDAQ">NASDAQ</exchange>: <ticker name="ALDX">ALDX</ticker>) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced an upcoming poster presentation at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting to be held November 10<sup>th</sup> -14<sup>th</sup> in San Francisco, CA. The presentation will summarize the results of a Phase 2 clinical trial of ADX-102 topical ophthalmic solution in a challenge model of allergic conjunctivitis in 100 subjects.</p>]]></description> <pubDate>Mon, 07 Nov 2016 13:00 GMT</pubDate> <dc:identifier>1082036</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Aldeyra Therapeutics</dc:contributor> <dc:modified>Tue, 19 Sep 2017 02:26 GMT</dc:modified> </item> </channel> </rss>